Wittgenbio
Is this your brand? Claim it — free, and takes a minute with your work email.
Overview
Tagline Brand's website · 2026-10-04
Unrivaled precision using Single-cell GenAI to extract cellular-level biomarkers from archived bulk RNA or pathological image data, offering 7x higher precision in identifying responders, 95% cost savings over traditional single-cell profiling, and regulator-ready patient stratification at trial scale without the single-cell burden.
Description Brand's website · 2026-10-04
Wittgenbio provides a Single-Cell GenAI powered Virtual Cell-to-Patient profiling technology to accelerate clinical success. Their platform transforms bulk RNA or pathological image data into regulator-ready patient stratification insights, de-risking clinical trials and enabling marker-driven therapeutic discovery.
Offerings
Core capabilities Brand's website · 2026-10-04
- Virtual Cell-to-Patient profiling technology
- LEIBER-X platform. These solutions provide single-cell clarity from bulk or image samples for patient stratification
- biomarker discovery
- and clinical trial de-risking.
Pricing Brand's website · 2026-10-04
Not explicitly mentioned, but implies a service or platform subscription model based on the value proposition of cost savings and accelerated research.
Audience
Target industry Brand's website · 2026-10-04
Clinical leaders, pharmaceutical companies, and academic partners involved in therapeutic development and patient stratification.
Is this your business?
The information above is publicly sourced — assembled by Optimly from Wittgenbio's website and public pages.
Claim this profile to publish your own verified Business Profile and speak for Wittgenbio across the index.
Claim Wittgenbio — free →Page last updated 2026-10-04.